Kolexia
Mouret-Reynier Marie-Ange Oncologie médicale
Mouret-Reynier Marie-Ange
Oncologie médicale
Centre Jean-Perrin
Clermont-Ferrand, France
270 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Métastase tumorale Tumeurs du sein triple-négatives Récidive tumorale locale Carcinome épithélial de l'ovaire Tumeur du sein de l'homme Carcinome canalaire du sein Carcinomes

Collaborateurs

Voir plus
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Petit Thierry
Petit Thierry
Centre Paul Strauss, Strasbourg, France
Ferrero Jean Marc
Ferrero Jean Marc
Centre Antoine Lacassagne, Nice, France

Industries

Voir plus
Lilly
43 collaboration(s)
Dernière en 2023
Novartis
43 collaboration(s)
Dernière en 2023
Seagen
22 collaboration(s)
Dernière en 2023
Pfizer
22 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
CUPCAKE: Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
Essai Clinique (Institut Curie)   06 mars 2024
MENOCOR: Study of the Impact of Chemo-induced Menopause on the Quality of Life in Young Women of Childbearing Age and Diagnosed With Non-metastatic Breast Cancer
Essai Clinique (Centre Jean-Perrin)   13 février 2024
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes.
ESMO open   12 février 2024
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Essai Clinique (Roche)   02 janvier 2024
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   21 décembre 2023
Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer.
JNCI cancer spectrum   19 décembre 2023
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC): Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015
Essai Clinique (BMS)   15 décembre 2023
NeoTOP: Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Essai Clinique (Unicancer)   06 décembre 2023